Display options
Cite
Batul SA, Gopinathannair R. Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal. J Atr Fibrillation. 2017;9(5):1499doi: 10.4022/jafib.1499.
Batul, S. A., & Gopinathannair, R. (2017). Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal. Journal of atrial fibrillation, 9(5), 1499. https://doi.org/10.4022/jafib.1499
Batul, Syeda Atiqa, and Gopinathannair, Rakesh. "Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal." Journal of atrial fibrillation vol. 9,5 (2017): 1499. doi: https://doi.org/10.4022/jafib.1499
Batul SA, Gopinathannair R. Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal. J Atr Fibrillation. 2017 Feb 28;9(5):1499. doi: 10.4022/jafib.1499. eCollection 2017. PMID: 29250266; PMCID: PMC5673382.
Copy Download .nbib Format: NLM
Share it on

J Atr Fibrillation. 2017 Feb 28;9(5):1499. doi: 10.4022/jafib.1499. eCollection 2017.

Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal.

Journal of atrial fibrillation

Syeda Atiqa Batul, Rakesh Gopinathannair

Affiliations

  1. Montefiore Medical Center, New York, NY and University of Louisville, Louisville, KY.

PMID: 29250266 PMCID: PMC5673382 DOI: 10.4022/jafib.1499

Abstract

Sotalol is a racemic mixture possessing beta-blocker and class III anti arrhythmic properties. Approved by US food and drug administration (FDA) since 2009 based on its bioequivalence with oral sotalol, clinicians are less familiar with the potential uses of the intravenous form despite its re-launch in United States in 2015. Available literature suggests that intravenous sotalol in recommended doses can be safely administered in adult and pediatric population achieving rapid reliable therapeutic plasma concentration and without additional proarrhythmic effects when compared to its oral form as well as other antiarrhythmic medications. Intravenous sotalol may have potential uses as an alternative agent for highly symptomatic atrial fibrillation post cardiac surgery as well as in life threatening ventricular arrhythmias. As with its oral form, judicious use with close attention to QTc and renal function is warranted. Further studies are needed to better understand the safety, efficacy and different dosing regimens of parenteral sotalol in adults and children.

Keywords: QT prolongation; atrial fibrillation; intravenous sotalol; post operative atrial arrhythmia; refractory ventricular arrhythmia; sotalol hydrochloride

References

  1. J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):86-92 - PubMed
  2. Cardiology. 2017;136(1):52-60 - PubMed
  3. Circulation. 2006 Jul 11;114(2):104-9 - PubMed
  4. J Atr Fibrillation. 2016 Feb 29;8(5):1359 - PubMed
  5. Am Heart J. 2004 Jan;147(1):E3 - PubMed
  6. Heart. 1998 Jun;79(6):568-75 - PubMed
  7. Acad Emerg Med. 2001 Feb;8(2):117-24 - PubMed
  8. Pediatr Cardiol. 2011 Oct;32(7):896-903 - PubMed
  9. J Cardiovasc Electrophysiol. 1996 Oct;7(10):952-61 - PubMed
  10. Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100 - PubMed
  11. Obstet Med. 2010 Mar;3(1):8-16 - PubMed
  12. Am J Med. 2011 Sep;124(9):875.e1-9 - PubMed
  13. Heart. 1999 Sep;82(3):319-24 - PubMed
  14. Eur J Clin Pharmacol. 1983;24(4):521-4 - PubMed
  15. Am J Cardiol. 1993 Aug 12;72(4):72A-79A - PubMed
  16. Am Heart J. 1971 Oct;82(4):439-47 - PubMed
  17. Am J Cardiol. 1990 Jan 2;65(2):28A-34A; discussion 35A-36A - PubMed
  18. Cardiology. 2010;116(3):219-25 - PubMed
  19. Pacing Clin Electrophysiol. 1997 Oct;20(10 Pt 1):2442-52 - PubMed
  20. Ann Emerg Med. 2000 Jul;36(1):1-9 - PubMed
  21. J Am Coll Cardiol. 2000 May;35(6):1434-41 - PubMed
  22. Expert Opin Pharmacother. 2015;16(17):2637-51 - PubMed
  23. Eur Heart J. 1995 Jan;16(1):81-6 - PubMed
  24. Eur Heart J. 2006 Aug;27(16):1979-2030 - PubMed
  25. Clin Pharmacol Ther. 1999 Jul;66(1):91-9 - PubMed
  26. Am J Ther. 2010 Jul-Aug;17(4):365-72 - PubMed

Publication Types